Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Entheon Biomedical Corp (CSE: ENBI )

0.1600 +0.0050 (+3.23%)
Streaming Delayed Price Updated: 11:30 AM EDT, Apr 26, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 525
Open 0.1600
Bid (Size) 0.1600 (6,000)
Ask (Size) 0.2200 (6,000)
Prev. Close 0.1550
Today's Range 0.1600 - 0.1600
52wk Range 0.0050 - 0.2500
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year 3 Year 5 Year

Top News

More News
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Poised to Accelerate Its CYB004 Clinical Development Program
Via Investor Brand Network
PsychedelicNewsBreaks – Cybin Inc. (NYSE American: CYBN) (NEO: CYBN) Acquires DMT Study Expected to Accelerate Clinical Development Path of CYB004
Via Investor Brand Network

Performance

YTD
+1500.00%
+1500.00%
1 Month
+28.00%
+28.00%
3 Month
+1500.00%
+1500.00%
6 Month
+1500.00%
+1500.00%
1 Year
+540.00%
+540.00%

More News

Read More
Entheon Biomedical Corp. (CSE: ENBI) (OTCQB: ENTBF) Featured in Virtual Coverage of Benzinga’s Small Cap Conference
Via Investor Brand Network
BTV Investor Alert Video: Entheon Biomedical Corp. - Treating Addiction
Via Newsfile
Entheon Biomedical Provides Corporate Update on Studies and Clinical Trials
Via Newsfile
Clinical Director of Imperial College's Center for Psychedelic Research Joins Entheon Advisory Board
Via Newsfile
Entheon Biomedical Corp. Announces DTC Eligibility
Via Newsfile
CORRECTION FROM SOURCE: BTV Examines the Rapidly Expanding Psychedelics Market
Via Newsfile
BTV Examines the Rapidly Expanding Psychedelics Market
Via Newsfile
Entheon Biomedical Announces Sponsorship of a Clinical Study to Assess the Electroneurophysiologic Effects of Ketamine
Via Newsfile
Exposures Product Safety
Entheon Biomedical Corp. Acquires Lobo Genetics Inc.
Via Newsfile
Topics Cannabis
Exposures Cannabis
Entheon Biomedical Further Strengthens Advisory Board with Appointment of Dr. Andy Greenshaw
Via Newsfile
Entheon Biomedical Announces Medical Advisor, Dr. Dinesh Bhayana
Via Newsfile
Entheon Subsidiary, HaluGen Life Sciences, Partners with Maya Health to Drive Psychedelics Genetic Test Kit Awareness
Via Newsfile
Entheon Biomedical Subsidiary, HaluGen Life Sciences, Announces Agreement with Third Wave
Via Newsfile
Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences and Silo Wellness Announces Psychedelics Genetic Test Kit Partnership
Via Newsfile
Entheon Biomedical Corp. Announces Agreement to Acquire Lobo Genetics Inc.
Via Newsfile
Topics Cannabis
Exposures Cannabis
Entheon Biomedical's Wholly-Owned Subsidiary, HaluGen Life Sciences, Psychedelics Genetic Test Kit Now Available for Sale in US
Via Newsfile
Entheon Biomedical Announces DMT Drug Supply Agreement with Ofichem Group
Via Newsfile
Entheon Biomedical Corp. Provides Corporate Update
Via Newsfile
Topics Artificial Intelligence
Exposures Artificial Intelligence Product Safety
Entheon Biomedical Lists on OTCQB Venture Market
Via Newsfile
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.